Guidances for the Respiratory Syncytial Virus Prophylactic Monoclonal Antibodies in Primary Care

Respiratory syncytial virus (RSV) is the primary viral pathogen responsible for acute lower respiratory tract infections in infants and young children, severely endangering children's health. In recent years, substantial advancements have been achieved in the field of RSV prevention worldwide. In China, the first RSV preventive monoclonal antibody has been approved for application. Meanwhile, multiple RSV monoclonal antibodies and vaccines are on the clinical trial stage. Based on the latest domestic and international practical experience, the expert group has formulated a guidance for the use of RSV preventive monoclonal antibodies in primary medical institutions in China through comprehensive discussions. This guidance consists of six parts: overview of RSV infection, populations eligible for prevention, prevention application regimens, management of adverse reactions, follow-up management, and health education. It aims to guide the standardized application of RSV preventive monoclonal antibodies in primary care, thus improving the prevention and control effectiveness of RSV infections in children.

呼吸道合胞病毒（Respiratory syncytial virus, RSV）是引发婴幼儿急性下呼吸道感染的主要病毒性病原体，严重威胁儿童健康。近年来，全球范围内RSV防控领域已取得显著进展。我国首款RSV预防性单克隆抗体已获批应用，与此同时多款RSV单克隆抗体及疫苗正处于临床试验阶段。专家组结合国内外最新实践经验，经充分研讨制定了《中国基层医疗机构RSV预防性单克隆抗体应用指南》。本指南共分为六个部分：RSV感染概述、预防适用人群、预防给药方案、不良反应处置、随访管理及健康教育，旨在指导基层医疗机构规范应用RSV预防性单克隆抗体，进而提升儿童RSV感染的防控成效。